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We studied the prevalence and clinical signi¢cance of
anti-U1 RNA antibodies in patients with systemic
sclerosis. The presence of anti-U1 RNA antibodies was
determined using immunoprecipitation in systemic
sclerosis patients with anti-U1 RNP antibodies (n¼ 36),
antitopoisomerase I antibodies (n¼ 20), or anticentro-
mere antibodies (n¼ 20), mixed connective tissue dis-
ease patients (n¼ 23), systemic lupus erythematosus
patients with anti-U1 RNP antibodies (n¼ 26), and nor-
mal controls (n¼ 20). Moreover, antigen speci¢cities for
anti-U1 RNP antibodies were examined in patients
with systemic sclerosis by immunoblotting and en-
zyme-linked immunosorbent assay. Anti-U1 RNA
antibodies was detected in 22 of 36 systemic sclerosis
patients (61%) with anti-U1 RNP antibodies, 14 of 23
patients (61%) with mixed connective tissue disease,
and eight of 26 systemic lupus erythematosus patients
(31%) with anti-U1 RNP antibodies. Anti-U1 RNA
antibodies were not detected in other groups. As for sys-
temic sclerosis patients, the frequencies of pulmonary
¢brosis and reduced percentage di¡usion capacity for
carbon monoxide were signi¢cantly greater in patients
with anti-U1 RNA antibodies than in those without
(76% vs 18%, po0.005; 82% vs 27%, po0.005, respec-
tively). Moreover, patients with anti-U1 RNA anti-
bodies had signi¢cantly lower percentage di¡usion
capacity for carbon monoxide and percentage vital ca-
pacity values than those without (51.9716.8 vs 79.4716.4,
po0.01; 83.8721.4 vs 101.4712.9, po0.05, respectively).
Regarding the antigen speci¢cities of anti-U1 RNP
antibodies in systemic sclerosis patients, the frequency
of anti-70 kDa antibodies determined by immunoblot-
ting was signi¢cantly higher in patients with anti-U1
RNA antibodies than in those without (77% vs 43%,
po0.05). This ¢nding was also con¢rmed by enzyme-
linked immunosorbent assay for anti-70 kDa antibodies
(86% vs 43%, po0.05). These results indicate that anti-
U1 RNA antibodies may be a serologic indicator
for pulmonary ¢brosis in systemic sclerosis patients
with anti-U1 RNP antibodies. Key words: anti-U1 RNP
antibody/pulmonary ¢brosis/scleroderma. J Invest Dermatol
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P
atients with collagen diseases often produce antibodies
against normal cellular components (Tan, 1989). Anti-
bodies against small nuclear ribonucleoproteins
(snRNPs), the protein^RNA complex, are mostly
found in sera from those patients, including anti-Sm
antibodies, anti-U1 RNP antibodies (anti-U1 RNP), and anti-
U3 RNP antibodies. Antigens of these antibodies are usually
protein components of snRNPs (van Venrooij and Sillekens,
1989). Anti-Sm antibodies, speci¢cally found in sera from patients
with systemic lupus erythematosus (SLE), are directed against the
B/B0 and D polypeptides of Sm snRNPs (Pettersson et al, 1984).
Anti-U1RNP, a serologic marker of mixed connective tissue dis-
ease (MCTD), are directed against the 70K, A, and C poly-
peptides of (U1)snRNPs (Pettersson et al, 1984). Anti-U3 RNP
antibodies, speci¢cally found in sera from patients with systemic
sclerosis (SSc), are also directed against a polypeptide component,
¢brillarin, of (U3)snRNPs (Lischwe et al, 1985). Thus, antibodies
against the RNA components of snRNPs, the U snRNAs, were
thought to be rare due to the poor immunogenicity of nucleic
acids (Chan and Tan, 1989; Tan, 1989). In 1986, however, anti-U1
RNA antibodies (anti-U1RNA) were ¢rst identi¢ed in a patient
with SLE overlap syndrome (Wilusz and Keene, 1986), and
further analyses demonstrated that stemloop-II or stemloop-IV
of U1 RNAwas a major epitope recognized by such antibodies
(Deutscher and Keene, 1986; vanVenrooij et al, 1990). vanVenrooij
et al (1990) reported that anti-U1RNAwere found in about 45%
of human anti-U1 RNP-positive sera, in about 30% of anti-U1
RNP-positive sera from patients with SLE, and in about 60% of
anti-U1 RNP-positive sera from patients with MCTD. Ho¡man
et al (1995) reported that anti-U1 RNA were positive in about
60% of connective tissue disease patients with anti-U1RNP.
As described above, the prevalence of anti-U1 RNA has al-
ready been established in patients with SLE or MCTD. The pre-
valence of anti-U1 RNA in patients with SSc, however, to our
knowledge, has not been described previously. In this study, we
performed immunoprecipitation using both protein^RNA com-
plex and protein-free naked RNA as substrates to determine the
prevalence of anti-U1 RNA and investigated the clinical signi¢-
cance of these antibodies in patients with SSc.
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MATERIALS AND METHODS
Patients Serum samples were obtained from 125 systemic rheumatic
disease patients ¢rst evaluated by rheumatologists in our division during
1990^99: 36 patients with SSc or SSc overlap syndrome positive for anti-
U1 RNP by immunodi¡usion [30 patients with SSc, two patients with
SSc and SLE, and four patients with SSc, SLE, and polymyositis (PM)],
20 SSc patients with antitopoisomerase I antibodies negative for anti-U1
RNP, 20 SSc patients with anticentromere antibodies negative for anti-U1
RNP, 23 patients with MCTD, and 26 SLE patients positive for anti-U1
RNP by immunodi¡usion. SSc patients with antitopoisomerase I
antibodies and anticentromere antibodies, MCTD patients, and SLE
patients with anti-U1 RNP were randomly selected. Three patients who
had been treated with corticosteroids or immunosuppressives were
excluded from the study because previous reports indicated the possibility
that these treatments might improve the skin and internal involvements. As
normal controls, 20 serum samples were also obtained from healthy
controls. Informed consent was obtained from all subjects. Of 36 patients
with SSc or SSc overlap syndrome positive for anti-U1 RNP, seven were
positive for antitopoisomerase I antibodies and one patient was positive for
anticentromere antibodies. The patients with SSc were grouped according
to the classi¢cation system proposed by Okano and Medsger (1990): 49
patients with limited cutaneous SSc (lcSSc), and 27 patients with di¡use
cutaneous SSc (dcSSc). All patients with dcSSc and 44 with lcSSc ful¢lled
the criteria proposed by the American College of Rheumatology
(formerly, the American Rheumatism Association) (Subcommittee for
Scleroderma Criteria of the American Rheumatism Association
Diagnostic and Therapeutic Criteria Committee, 1980). All ¢ve patients
with lcSSc who did not meet these criteria had sclerodactyly and at least
two other features of the CREST syndrome (calcinosis, Raynaud’s
phenomenon, esophageal dysmotility, telangiectasia). For a diagnosis of
MCTD, the criteria proposed byAlarcon-Segovia and Cardiel (1989) were
used. In this study, patients with MCTD had anti-U1 RNP and clinical
features of SLE, SSc, and PM, but did not satisfy the criteria for other
connective tissue diseases, such as SLE, SSc, or PM/dermatomyositis
(Bohan and Peter, 1975). Patients with SLE met the American
Rheumatism Association criteria for de¢nite SLE (Tan et al, 1982). Patients
who met two or more diagnostic criteria for these connective tissue
diseases were distinguished from MCTD and diagnosed with overlap
syndrome. Aliquots of sera were frozen at 801C until assayed.
Clinical assessment The clinical and laboratory data reported in this
study were obtained at the time the blood samples were drawn. Patients
with SSc were evaluated for the presence of gastrointestinal, pulmonary,
cardiac, renal or joint involvement, as follows. Esophagus hypomotility
was de¢ned as distal esophageal hypomotility on barium-contrast
radiography. Pulmonary interstitial ¢brosis was de¢ned as bibasilar
interstitial ¢brosis on chest radiographs, and in patients with no
abnormalities on chest radiographs early pulmonary interstitial ¢brosis
was de¢ned as alveolitis on high-resolution computer tomography.
Cardiac involvement was de¢ned as any of the following: symptomatic
pericarditis, clinical evidence of left ventricular congestive heart failure, or
arrhythmias requiring treatment. Renal involvement was de¢ned as
malignant hypertension and/or rapidly progressive renal failure. Skeletal
muscle involvement was de¢ned as proximal muscle weakness and
elevated serum creatine kinase levels, plus abnormal electromyographic
¢ndings consistent with myopathy and/or histopathologic changes in
in£ammatory myopathy. Joint involvement was de¢ned as in£ammatory
polyarthralgia or arthritis. Disease onset was de¢ned as the date of the
¢rst appearance of Raynaud’s phenomenon. Duration of disease was
de¢ned as the interval between the onset and the ¢rst physician diagnosis.
All SSc patients were followed through June 2000.
Analysis of antinuclear antibodies Antinuclear antibodies were
detected via immuno£uorescence using HEp-2 cells as a substrate, as
described previously (Takehara et al, 1983; Ihn et al, 1996).
Double immunodi¡usion Antibodies against U1 RNP and topoiso-
merase-I antigens were detected using double immunodi¡usion in 0.5%
agarose, as described previously (Fujimoto et al, 1997).
Immunoprecipitation Immunoprecipitation using HeLa cell extracts
was performed. A total of 10 ml of each patient’s sera was mixed with 2
mg of protein A^Agarose CL-4B (Pharmacia Biotech, Uppsala, Sweden)
in 500 ml of an IPP bu¡er (10 mM Tris^HCl, pH 8.0, 500 mM NaCl, 0.1%
Nonidet P-40) and incubated with rotation overnight at 41C. The IgG-
coated agarose was washed three times in 750 ml of an IPP bu¡er using
15 s spins in a microfuge tube, and then resuspended in 500 ml of NET-2
bu¡er (50 mM Tris^HCl, pH 8.0, 150 mM NaCl, 0.05% Nonidet P-40).
For analysis of antibodies against naked RNA, this suspension was
incubated with 200 ml of an extract of protein-free naked RNA, which
was prepared from 3106 cells by deproteinization with phenol/
chloroform/isoamyl alcohol (50 : 50 : 1; containing 0.1% 8-hydroxy-
quinolone), on a rotator for 2 h at 41C. The Ag-bound agarose was then
collected via a 15 s centrifugation in a microfuge, washed three times with
NET-2 bu¡er, and resuspended in 300 ml of NET-2 bu¡er. To extract
bound RNAs, 30 ml of 3.0 M sodium acetate, 30 ml of 10% sodium
dodecyl sulfate (SDS), 1 ml of glycogen, and 300 ml of phenol/chloroform/
isoamyl alcohol were added to the agarose beads. After agitation in a
Vortex mixer and spinning in a microfuge for 3 min, RNAs were
recovered in the aqueous phase, precipitated with ethanol, and dissolved
in 20 ml of an electrophoresis sample bu¡er composed of 10 M urea,
0.025% bromophenol blue, and 0.025% xylene cyanol-FF in a TBE bu¡er
(90 mM Tris^HCl, pH 8.6, 90 mM boric acid, and 1 mM ethylenediamine
tetraacetic acid). The RNA samples were denatured at 651C for 3 min,
resolved in a 7 M urea^10% polyacrylamide gel, and stained with silver
(Bio-Rad Laboratories, Hercules, CA). In certain experiments, for analysis
of antibodies against protein^RNA complex, the same procedures were
performed using an extract of RNA^protein complex, which was
prepared from 3106 cells without deproteinization.
Preparation of nuclear extracts for immunoblotting Nuclear
extracts were prepared as described previously (Habets et al, 1983; Ihn et al,
1997). Brie£y, con£uent HeLa cells from two 150 mM dishes were washed
with phosphate-bu¡ered saline and scraped into 1 ml of cold bu¡er A (10
mM HEPES^KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl £uoride) at 41C. The cells
were allowed to swell on ice for 10 min and were then vortexed for 10 s.
After centrifugation for 3 min, the supernatant was discarded. The pellet
was resuspended in 100 ml of cold bu¡er C (20 mM HEPES^KOH pH
7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM ethyl-
enediamine tetraacetic acid, 1 mM dithiothretiol, 0.7 mM
phenylmethylsulfonyl £uoride) and incubated on ice for 30 min for high-
salt extraction. Cellular debris was removed by centrifugation for 2 min at
41C and the supernatant fraction was stored at ^801C until used for
immunoblotting.
Immunoblotting Immunoblotting was performed as described
previously (Sato et al, 1994; Ihn and Trojanowska, 1997). Brie£y, nuclear
antigens from HeLa cells were subjected to electrophoresis on 4%^20%
gradient SDS^polyacrylamide slab gels, and then electrotransferred from
the gels onto nitrocellulose sheets. The nitrocellulose sheets were then
incubated overnight with serum samples diluted 1 : 100. Bound antibodies
were detected with an alkaline-phosphatase-conjugated goat antihuman
IgG antibody, and color was developed with nitroblue tetrazolium and
5-bromo-4-chloro-3-indolyl phosphatase.
Enzyme-linked immunosorbent assay (ELISA) for anti-70 kDa
antibodies A speci¢c ELISA kit for anti-70 kDa antibodies (MBL,
Aichi, Japan) was used to determine the prevalence of anti-70 kDa
antibodies in SSc or SSc overlap syndrome patients with anti-U1 RNP.
This ELISA kit was prepared as described previously with minor
modi¢cation (Habets et al, 1989; ter Borg et al, 1991). In brief, the insoluble
b-galactosidase^70 kDa fusion protein produced by MBL was solubilized
in 6 M urea and diluted (1 : 100) in coating bu¡er (15 mM Na2CO3, 35 mM
NaHCO3, pH 9.6). One hundred microliters of fusion protein diluted in
coating bu¡er were brought into each well of microtiter plates and
allowed to coat overnight at 41C. Plates were washed ¢ve times with
PBST (PBSþ 0.05% Tween 20) and remaining binding sites were
blocked with 1% bovine serum albumin in PBST for 2 h at room
temperature. Plates were washed again ¢ve times with PBST.
According to the manufacturer’s instructions, 36 sera from SSc or SSc
overlap syndrome patients with anti-U1 RNP were measured. As normal
controls, 20 sera from the healthy population used in immunoprecipitation
were also measured. In brief, a microtiter plate prepared as described above
was incubated with 100 ml of 201-fold diluted serum at room temperature
for 1 h. Then, the plate was washed and incubated at room temperature
for 1 h with 100 ml of 101-fold diluted horseradish peroxidase conju-
gated antihuman IgG. Next, the plate was washed again, 100 ml of
tetramethylbenzene was added, and incubation was performed at room
temperature for 30 min. Finally, 2 mmol per l NaN3 was added to
terminate the peroxidase reaction and the absorbance at 450 nm was
measured. Sera with optical density (OD) 450 nm values more than 2SD
greater than the mean value in the normal controls were regarded as
positive for anti-70 kDa antibodies.
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Statistical analysis Statistical analysis was carried out with Mann^
Whitney’s U test and Fisher’s exact probability test for the analysis of
frequency. Two-tailed p-valueso0.05 were considered signi¢cant.
RESULTS
Prevalence of anti-U1 RNA Figure 1 shows representative
results of immunoprecipitation. RNP immunoprecipitation was
performed using an extract of RNA^protein complex, whereas
RNA immunoprecipitation was performed using an extract of
protein-free naked RNA. Sera with U1 RNA in both RNP and
RNA immunoprecipitation were regarded as positive for anti-U1
RNP and anti-U1 RNA (Fig 1, lanes 4, 5). Sera with U1 RNA
only in RNP immunoprecipitation were regarded as sera with
anti-U1 RNP negative for anti-U1 RNA (Fig 1, lanes 6, 7). As
shown in Fig 1(b), many sera from SSc or SSc overlap
syndrome patients with anti-U1 RNP revealed U1 RNA in
RNA immunoprecipitation. Results are summarized in Table I.
Anti-U1 RNAwere present in 22 of 36 patients (61%) with SSc
or SSc overlap syndrome positive for anti-U1 RNP, 17 of 30
patients (57%) with SSc positive for anti-U1 RNP, 14 of 23
patients (61%) with MCTD, and eight of 26 patients (31%) with
SLE positive for anti-U1RNP. There were signi¢cant di¡erences
between the SLE patient group and the other three groups
described above (po0.05, respectively). There were no cases with
anti-U1 RNA in 20 SSc patients positive for antitopoisomerase I
antibodies, 20 SSc patients positive for anticentromere antibodies,
and 20 normal controls.
Antigen speci¢city for anti-U1 RNP Figure 2 shows
representative results of immunoblotting and these results are
summarized in Table II. In immunoblotting, anti-70 kDa
antibodies, anti-A protein antibodies, and anti-C protein
antibodies were detected in 23 of 36 patients (64%), 30 of 36
patients (83%), and four of 36 patients (11%) respectively with
SSc or SSc overlap syndrome positive for anti-U1RNP.
The frequency of anti-70 kDa antibodies was signi¢cantly
higher in SSc or SSc overlap syndrome patients with anti-U1
RNA than in those without (77% vs 43%, po0.05). There was
no signi¢cant di¡erence in the frequencies of anti-A and anti-C
protein antibodies between these two patient groups. Excluding
six overlap syndrome patients, 17 of 30 patients (57%), 25 of 30
patients (83%), and four of 30 patients (13%) had anti-70 kDa,
anti-A, and anti-C proteins, respectively. The frequency of
anti-70 kDa was also signi¢cantly higher in SSc patients with
anti-U1RNA than in those without (71% vs 38%, po0.05).
As described above, there is a signi¢cant di¡erence in the
presence of anti-70 kDa antibodies between sera from SSc or
SSc overlap syndrome patients with anti-U1 RNA and those
without. To con¢rm this ¢nding, we also performed ELISA for
anti-70 kDa antibodies using sera from SSc or SSc overlap
syndrome patients with anti-U1 RNP. The cut-o¡ value
(meanþ 2SD) was set at 0.50, based on data of the 20 healthy
control sera. As shown in Fig 3, there was a signi¢cant
di¡erence in the frequencies of anti-70 kDa antibodies between
patients with anti-U1 RNA and those without (86% vs 43%,
po0.05). Excluding six patients with overlap syndrome (shown
as open circles and crosses in Fig 3), the frequency of anti-70
kDa antibodies was again signi¢cantly higher in patients with
anti-U1 RNA than in those without (82% vs 38%, po0.05). All
of 23 sera that reacted with the 70 kDa protein in
immunoblotting were also positive for anti-70 kDa antibodies in
ELISA. Of 13 sera without anti-70 kDa in immunoblotting, two
sera were positive and the remaining 11 sera were negative for
anti-70 kDa antibodies in ELISA. These results indicate that
ELISA is a more sensitive technique for the detection of anti-70
kDa antibodies than immunoblotting.
Clinical and serologic correlations The clinical and serologic
features of SSc or SSc overlap syndrome patients with or without
anti-U1 RNA are shown in Table III. To focus on the
signi¢cance of anti-U1 RNA, SSc or SSc overlap syndrome
patients with antitopoisomerase I antibodies or anticentromere
antibodies were excluded. There was no signi¢cant di¡erence
between these groups in terms of sex. Age of onset in patients
Figure1. RNP and RNA immunoprecipitation with sera from
patients with SSc. Immunoprecipitations of RNP complexes (a, lanes
2^4, 6; b, lanes 2^4) and naked RNA (a, lanes 5, 7; b, lanes 5^11) were carried
out as described in Materials and Methods. (a) Lane 1, total RNA; lane 2, nor-
mal human serum; lane 3, serum from an SSc patient with anti-U3 RNP
antibodies; lanes 4, 5, serum from an SSc patient with both anti-U1 RNP
antibodies and anti-U1 RNA antibodies; lanes 6, 7, serum from an SSc
patient with anti-U1 RNP antibodies negative for anti-U1 RNA antibo-
dies. Note the presence of U1 RNA in lane 5 and the absence in lane 7. (b)
Lane 1, total RNA; lane 2, normal human serum; lane 3, serum from an
SLE patient with anti-Sm antibodies; lane 4, serum from an SSc patient
with anti-U3 antibodies; lanes 5^11, serum from SSc patients with anti-U1
RNA antibodies.
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with anti-U1 RNA was signi¢cantly higher than in those
without (43.3711.3 y vs 33.377.9 y, po0.005) and disease
duration prior to diagnosis in patients with anti-U1 RNA
was signi¢cantly shorter than in those without (4.673.9 y vs
12.677.1 y, po0.005). There was no signi¢cant di¡erence in the
frequency of dcSSc between patients with anti-U1 RNA and
those without. Though there were no clinically signi¢cant
di¡erences, neither calcinosis nor renal disease was detected in
SSc patients with anti-U1 RNA. The frequencies of pulmonary
¢brosis (PF) and reduced percentage di¡usion capacity for
carbon monoxide were signi¢cantly greater in patients with
anti-U1 RNA than in those without (76% vs 18%, po0.005;
82% vs 27%, po0.005, respectively). The frequency of reduced
percentage vital capacity was also greater in patients with
anti-U1 RNA than in those without (41% vs 18%), but there
was no signi¢cant di¡erence. Moreover, patients with anti-U1
RNA had signi¢cantly lower percentage di¡usion capacity for
carbon monoxide values and percentage vital capacity values
than those without (51.9716.8 vs 79.4716.4, po0.01; 83.8721.4
vs 101.4712.9, po0.05, respectively).
To further con¢rm the signi¢cance of anti-U1 RNA, we
investigated the prevalence of PF in SSc patients with
antitopoisomerase I antibodies, anticentromere antibodies, or
anti-U1 RNA. The prevalence of PF in SSc patients with
antitopoisomerase-I antibodies is signi¢cantly elevated compared
with those without (78% vs 38%, po0.005). The prevalence
of PF in SSc patients with anticentromere antibodies is
signi¢cantly decreased compared with those without (19% vs
67%, po0.0005). These results are consistent with previous
reports (Steen et al, 1988). The prevalence of PF in patients with
U1 RNAwas also elevated compared with those without (80%
vs 39%, po0.05).
We also investigated the association of anti-U1 RNA with
PF in patients with MCTD. The prevalence of PF in MCTD
patients with anti-U1 RNA was elevated compared with
those without (50% vs 30%), but there was no signi¢cant
di¡erence. Regarding SLE, no patients had interstitial
pulmonary involvement.
DISCUSSION
This study was a comprehensive analysis of the distribution of
anti-U1 RNA in patients with connective tissue disease. Anti-
U1 RNAwas detected in 44 of 85 patients (52%) with anti-U1
RNP, including 22 of 36 patients (61%) with SSc or SSc overlap
syndrome, 14 of 23 patients (61%) with MCTD, and eight of 26
patients (31%) with SLE. No cases with anti-U1 RNAwere de-
tected in SSc patients with antitopoisomerase I antibodies or an-
ticentromere antibodies negative for anti-U1RNP, and in normal
controls. These results are consistent with previous reports that
anti-U1 RNA was always accompanied by anti-U1 RNP and
was detected in about 45%^60% of connective tissue disease pa-
tients with anti-U1 RNP, about 30% of SLE patients with anti-
U1 RNP, and about 60% of MCTD patients (vanVenrooij et al,
1990; Ho¡man et al, 1995). Previous reports suggested that anti-
U1 RNA was con¢ned to sera from patients with SLE or SLE
overlap syndrome, but was rarely found in sera from patients
with other connective tissue diseases (Wilusz and Keene, 1986;
vanVenrooij et al, 1990; Ho¡man et al, 1995). In this study, exclud-
ing six patients with overlap syndrome, however, 17 of 30 sera
samples (57%) from SSc patients with anti-U1 RNP were posi-
tive for anti-U1 RNA. This result suggests that the presence of
anti-U1 RNA in sera from patients with SSc is not rare. To our
knowledge, this is the ¢rst report indicating the prevalence of
anti-U1RNA in SSc patients and the prevalence of this antibody
in other ethnic groups remains to be con¢rmed. The frequencies
of di¡erent autoantibodies in patients with SSc show considerable
variation among di¡erent ethnic groups (McNeilage et al, 1989;
Reveille et al, 1992; Kuwana et al, 1994). Multiple factors linked
to ethnicity, including genetic and environmental factors, appear
to in£uence autoantibody status in SSc (Kuwana et al, 1999). More
information from di¡erent ethnic groups would give insight into
the exact prevalence of anti-U1RNA in patients with SSc.
Table I. Frequencies of anti-U1 RNA antibodies (anti-UI
RNA) in patients with systemic sclerosis (SSc) or SSc overlap
syndrome, systemic lupus erythematosus (SLE), and
mixed connective tissue disease (MCTD), detected by
immunoprecipitation
Anti-U1 RNA [%]
SSc or SSc overlap syndrome patients with anti-
U1RNP (n¼ 36)
22 (61)
SSc patients with anti-U1 RNP (n¼ 30) 17 (57)
SSc patients with anti-topo I negative for anti-
U1RNP (n¼ 20)
0 (0)
SSc patients with ACA negative for anti-U1
RNP (n¼ 20)
0 (0)
SLE patients with anti-U1RNP (n¼ 26) 8 (31)
MCTD patients (n¼ 23) 14 (61)
Normal controls (n¼ 20) 0 (0)
Unless indicated otherwise, values are numbers.
anti-U1 RNP, anti-U1 RNP anti-body; anti-topo I, anti-topoisomerase I anti-
body; ACA, anti-centromere antibody.
Figure 2. Immunoblot analysis of sera from SSc patients with anti-
U1 RNP antibodies positive for anti-U1 RNA antibodies (a) and pa-
tients with anti-U1 RNP antibodies negative for anti-U1 RNA anti-
bodies (b). Nitrocellulose blot strips contained HeLa nuclear extracts
transferred after separation on 4%^20% gradient SDS^polyacrylamide
gels. Each strip was incubated with the patient’s serum at a 1 : 100 dilution
and bound antibodies were detected with an alkaline-phosphatase-conju-
gated goat antihuman IgG antibody; color was developed with nitroblue
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphatase.
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This study and previous studies indicated that anti-U1 RNA
was always accompanied by anti-U1RNP.These results strength-
en the hypothesis that the induction of an immune response to
one component of an autoantigenic (U1)snRNP complex, such
as 70K, can induce the diversi¢cation of autoantibodies to other
components of the (U1)snRNP complex, including U1 RNA.
Recent reports have suggested that predictable, orderly patterns
of emergence of anti-U1 RNP responses occur in humans as
well as animal models of autoimmune diseases (James et al, 1995).
Greidinger and Ho¡man (2001) reported that 70K is predomi-
nant in early RNP antigens and immunity to A and C develops
most often as a consequence of spreading. Our ¢nding
that the prevalence of anti-70 kDa antibodies is signi¢cantly
increased in SSc patients with anti-U1 RNA is consistent with
this theory.
We previously reported that anti-U1 RNP was closely corre-
lated with PF and joint involvement in patients with SSc (Ihn et
al, 1999). In this study, we showed that the presence of anti-U1
RNAwas closely correlated with PF in patients with SSc or SSc
overlap syndrome positive for anti-U1RNP. Regarding joint in-
volvement, there was no signi¢cant correlation with the presence
of anti-U1 RNA. These results indicate that anti-U1 RNA may
serve as a useful serologic indicator of PF in SSc patients with
anti-U1 RNP. We also investigated the association of anti-U1
RNAwith PF in all SSc patients.The prevalence of PF in patients
with anti-U1RNAwas also elevated compared with those with-
out (80% vs 39%, po0.05). These results suggest that anti-U1
RNA also serve as a marker of PF in all SSc patients.
Figure 3. Prevalence of anti-70 kDa antibodies in sera from SSc or
SSc overlap syndrome patients with anti-U1 RNP determined by
ELISA. The dashed line indicates the cut-o¡ value (0.50), based on data of
20 healthy control sera. Closed circles show patients with SSc. Open circles
show patients with SSc and SLE. Crosses show patients with SSc, SLE,
and PM. Anti-70 kDa antibodies were found in 19 of 22 patients (86%)
with anti-U1RNA and in six of 14 patients (43%) without anti-U1RNA.
Table II. Antigen speci¢city of anti-U1 RNP antibodies (anti-U1 RNP) determined by immunoblotting in patients with systemic
sclerosis (SSc) or SSc overlap syndrome positive or negative for anti-U1 RNA antibodies (anti-U1 RNA)
70 kD (%) A (%) C (%)
SSc or SSc overlap syndrome patients with anti-U1RNP (n¼ 36) 23 (64) 30 (83) 4 (11)
SSc or SSc overlap syndrome patients with anti-U1RNA (n¼ 22) 17 (77)n 19 (86) 2 (9)
SSc or SSc overlap syndrome patients without anti-U1RNA (n¼14) 6 (43)n 11 (79) 2 (14)
Unless indicated otherwise, values are numbers.
A, anti-A protein antibody; C, anti-C protein antibody.
npo0.05.
Table III. Correlation of anti-U1 RNAwith clinical features in
28 patients with SSc
Patients with
anti-U1RNA
(n¼17)
Patients without
anti-U1RNA
(n¼11)
Sex (male : female) 1 : 16 0 : 11
Age of onset (y) 43.3711.3n 33.377.9n
Duration of disease (y) 4.673.9n 12.677.1n
Clinical features
Skin sclerosis (lcSSc : dcSSc) 13 : 4 11 : 1
Pitting scars/ulcers 41 (7/17) 45 (5/11)
Short sublingual frenulum 53 (9/17) 45 (5/11)
Contracture of phalanges 41 (7/17) 36 (4/11)
Hyperpigmentation 18 (3/17) 9 (1/11)
Calcinosis 0 (0/17) 36 (4/11)
Telangiectasia 71 (12/17) 55 (6/11)
Nailfold bleeding 65 (11/17) 64 (7/11)
Raynaud’s phenomenon 100 (17/17) 100 (11/11)
Organ involvement
Esophagus 63 (10/16) 60 (6/10)
Lung 76 (13/17)n 18 (2/11)n
Decrease %DLco 82 (14/17)n 27 (3/11)n
Decrease %VC 41 (7/17) 18 (2/11)
Heart 29 (5/17) 27 (3/11)
Kidney 0 (0/17) 27 (3/11)
Muscle 29 (5/17) 18 (2/11)
Joint 65 (11/17) 100 (11/11)
Laboratory ¢ndings
Elevated ESR 100 (17/17) 91 (10/11)
Increased CRP 18 (3/17) 9 (1/11)
Unless noted otherwise, values are percentages.
SSc, di¡use cutaneous SSc; lcSSc, limited cutaneous SSc; VC, vital capacity;
DLCO, di¡usion capacity for carbon monoxide; LDH, lactate dehydrogenase;
ESR, erythrocyte sedimentation rate (normalo15 mm per h); CRP, c-reactive
protein (normalo0.3 mg per dl).
npo0.005.
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In this study, we demonstrated that disease duration prior to
diagnosis was signi¢cantly shorter in SSc patients with anti-U1
RNA than in those without. Most patients without anti-U1
RNA had a prolonged clinical phase of Raynaud’s phenomenon
prior to de¢nite diagnosis of SSc. This may re£ect that SSc pa-
tients with anti-U1 RNA usually reveal typical symptoms
whereas anti-U1 RNP positive, anti-U1 RNA negative SSc pa-
tients had mild symptoms. Ho¡man et al (1995) reported that an
anti-RNP positive, anti-U1 RNA negative group consisted of
patients with various symptoms of mild MCTD and SLE,
whereas an anti-U1RNA positive group comprised patients with
more typical MCTD features. These results suggested that anti-
U1RNA may be useful in the classi¢cation of patients with con-
nective tissue diseases, including SSc, SLE, and MCTD, who are
positive for anti-U1 RNP and may serve as a serologic indicator
for the typical type of these diseases.
We also determined the antigen speci¢city of anti-U1RNP in
SSc patients with anti-U1RNP. In immunoblotting, the frequen-
cies of anti-70 kDa, anti-A, and anti-C protein antibodies were
64%, 83%, and 11%, respectively. These results were consistent
with our previous reports (Ihn et al, 1999). The frequency of anti-
70 kDa antibodies was signi¢cantly higher in patients with SSc or
SSc overlap syndrome positive for anti-U1 RNA than in those
negative for anti-U1RNA (77% vs 43%, po0.05).This di¡erence
in the frequency of anti-70 kDa antibodies is also con¢rmed
using ELISA (86% vs 43%, po0.05). Regarding the titer of
anti-70 kDa antibodies in patients with overlap syndrome, pre-
vious papers reported as follows. (i) In the group of overlap syn-
drome patients with SLE and SSc, anti-U1 RNP were directed
in lower titers against the 70 kDa protein. (ii) In the group of
overlap syndrome patients with SLE, SSc, and PM, a strong
anti-70 kDa antibody level was predominant (Habets et al, 1983;
van Venrooij, 1987). In this study, all sera from six patients with
overlap syndrome had anti-70 kDa antibodies. Four sera from
patients with SLE, SSc, and PM (shown as crosses in Fig 3)
revealed OD 450 nm values ranging from 1.68 to 2.67, whereas
two sera from patients with SLE and SSc (shown as open circles
in Fig 3) revealed OD 450 nm values of 0.93 and 1.17. These re-
sults seem to be consistent with previous reports. Excluding these
six patients, the frequencies of anti-70 kDa, anti-A, and anti-C
protein antibodies in patients with SSc were also consistent with
our previous reports (57%, 83%, and 13%, respectively) and the
frequencies of anti-70 kDa antibodies determined by immuno-
blotting and ELISAwere also signi¢cantly higher in SSc patients
with anti-U1RNA than in those without (71% vs 38%, po0.05;
82% vs 38%, po0.05, respectively). As there was a signi¢cant
correlation between the presence of anti-U1 RNA and anti-70
kDa antibodies in patients with SSc or SSc overlap syndrome,
we also assessed whether or not anti-70 kDa antibodies were cor-
related with PF. There was no signi¢cant di¡erence in the fre-
quency of PF between patients with anti-70 kDa antibodies and
those without (64% vs 50%).
In conclusion, we demonstrated that anti-U1 RNA may be
useful in the classi¢cation of patients with anti-U1 RNP in SSc,
as well as SLE and MCTD, and serve as a useful indicator of PF
in SSc patients with anti-U1RNP.
This study is supported in part by a grant for scienti¢c research from the Japanese
Ministry of Education (10770391), and by project research for progressive systemic
sclerosis from the Japanese Ministry of Health andWelfare.
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